

pVITRO2-hgro-mcs

A multigenic plasmid for high levels of expression

Catalog code: pvitro2-mcs

<https://www.invivogen.com/pvitro2-mcs>

For research use only

Version 19A21-MM

PRODUCT INFORMATION

Contents

- 20 µg of pVITRO2-hgro-mcs provided as lyophilized DNA
- 1 ml Hygromycin B Gold at 100 mg/ml

Storage and stability

- Product is shipped at room temperature.
- Upon receipt, store lyophilized DNA at -20°C.
- Resuspended DNA should be stored at -20°C.
- Store Hygromycin B Gold at 4°C or -20°C. The expiry date is specified on the product label.

Quality control

- Plasmid construct has been confirmed by restriction analysis and sequencing.
- Plasmid DNA was purified by ion exchange chromatography and lyophilized.

GENERAL PRODUCT USE

pVITRO is a family of plasmids developed mainly for in vitro studies. They allow the ubiquitous and constitutive co-expression of two genes of interest. pVITRO plasmids can be stably transfected in mammalian cells and the genes of interest are expressed at high levels. Each pVITRO plasmid is available with either two multiple cloning sites or two reporter genes.

pVITRO2-hgro-mcs plasmid is selectable with hygromycin B in both *E. coli* and mammalian cells. It contains two multiple cloning sites (MCS) for the convenient cloning of two cDNAs.

METHODS

Plasmid resuspension:

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile water. Store resuspended plasmid at -20°C.

Plasmid amplification and cloning:

Plasmid amplification and cloning can be performed in *E. coli* GT116 or other commonly used laboratory *E. coli* strains, such as DH5α.

Hygromycin B usage:

This antibiotic can be used for *E. coli* at 50-100 µg/ml in liquid or solid media and at 50-500 µg/ml to select Hygromycin-resistant mammalian cells.

PLASMID FEATURES

• hFerH and hFerL composite promoters: Ferritin is a 24 subunit protein composed of two subunit types, termed H (heavy) and L (light), which perform complementary functions in the protein. Ferritin is ubiquitously expressed. Its synthesis is highly regulated by the iron status of the cell. The iron regulation is achieved at the translational level through the interaction between the iron-responsive element (IRE), located in the 5' untranslated region (5'UTR) of the ferritin mRNAs, and the iron regulatory protein¹. To eliminate the iron regulation of the ferritin promoters, the 5'UTR of FerH and FerL have been replaced by the 5'UTR of the mouse and chimpanzee elongation factor 1 (EF1) genes, respectively.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3622-3480

E-mail: info@invivogen.com

• **SV40 enhancer** which is comprised of a 72-base-pair repeat allows the enhancement of gene expression in a large host range². The enhancement varies from 2-fold in non-permissive cells to 20-fold in permissive cells.

• **CMV enhancer:** The major immediate early enhancer of the human cytomegalovirus (HCMV), located between nucleotides -118 and -524, is composed of unique and repeated sequence motifs. The HCMV enhancer can substitute for the 72-bp repeats of SV40 and is severalfold more active than the SV40 enhancer³.

• **SV40 pAn:** the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA. The efficiency of this signal was first described by Carswell *et al.*⁴

• **pMB1 ori:** a minimal *E. coli* origin of replication to limit vector size, but with the same activity as the longer Ori.

• **FMDV IRES:** The internal ribosome entry site of the Foot and Mouth Disease Virus enables the translation of two open reading frames from one mRNA with high levels of expression⁵.

• **EM7** is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.

• **hph gene** confers resistance to Hygromycin B both in *E. coli* and mammalian cells. In bacteria, *hph* is expressed from the constitutive *E. coli* EM7 promoter. In mammalian cells, *hph* is transcribed from the CAG promoter as a polycistronic mRNA and translated via the FMDV IRES.

• **EF1 pAn** is a strong polyadenylation signal. InvivoGen uses a sequence starting after the stop codon of the EF1 cDNA and finishing after a bent structure rich in GT.

• **MCS1 and MCS2:** Each multiple cloning site contains several restriction sites that are compatible with many other enzymes, thus facilitating cloning.

MCS1 contains the following restriction sites:

Age I, Eco RV, Bam HI, Sal I and Avr II


- Age I is compatible with Bsp EI and Sgr AI.
- Eco RV (blunt-end restriction enzyme).
- Bam HI is compatible with Bgl II, Bst YI and Bcl I.
- Sal I is compatible with Ava I and Xho I.
- Avr II is compatible with Xba I, Spe I and Nhe I.

MCS2 contains the following restriction sites:

Sgr AI, Bgl II, Xho I and Nhe I

- Sgr AI is compatible with Bsp EI and Age I.
- Bgl II is compatible with Bam HI, Bst YI and Bcl I.
- Xho I is compatible with Ava I and Sal I.
- Nhe I is compatible with Xba I, Spe I and Avr II.

1. Kim DW. *et al.* 1990. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 91:217-23. 2. Moreau P. *et al.*, 1981. The SV40 72 base repeat repeat has a striking effect on gene expression both in SV40 and other chimeric recombinants. Nucleic Acids Res. 9:6047-68. 3. Boshart M. *et al.* 1985. A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus. Cell 141:521-30. 4. Carswell S., and Alwine JC. 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. Mol. Cell Biol. 10: 4248-58. 5. Ramesh N. *et al.* 1996. High-titer bicistronic retroviral vectors employing foot-and-mouth disease virus internal ribosome entry site. Nucleic Acids Res. 24(14):2697-700.



3301 *gtagcctcgccctcggtccggcttgaggcctagcggtgtccgcgcgcgcgtactccggccgactctggctttttttttgttgg*
 3401 *ttgcccgtgcctcgattggcggtcagcaatagggtacaacaaaggagggtcgccccggagccggagggatgggtcggtggggagg*
 3501 *aatggaggacaggagtggcgctggggccgccttcggagcacatgtccgacgccacccggatggggcgaggcctgggtttccgaac*
 3601 *caggctgggttagcggtccgaggccatgtggcccccagcacccggacatctggctggcgccgcgtgcctccctaactagggtgaggcc*
 3701 *Smal (3745)*
 3701 *atcccgccggcaccagttcggtcggtggaaagatggccgtccggccctgttgcacggactcaaaatggaggacgcggcagccgggtggagcgggc*
 3801 *gggtgagtccacccacacaaaaggaaagaggcctggccctcaccggctgtgtccctgtgacccgtggctatcgcccaatagtacacccggctt*
 3901 *ttgagcacggctagtcgcggcgggggggatgtaatggcggtggagttgttgcacattgggtggagactagtcaggccagcctggcgctggaa*
 4001 *gtcattttggaaattgtccctttagtttgcggagctaattctcggttttagcggttcaaaggatctttaaacccttttagGTGTTGTG*
EcoRV (4132) MluI (4142) SalI (4155)
AgeI (4124) BamHI (4136) ClaI (4149) AvrII (4161)
 4101 AAAACCACCGCTAATTCAAAGCAACCGTGTATCGATCCACCGGTATCGATTGTCGACCCCTAGGAGCAGGTTCCCCAATGACACAAACGTGCAACT
 4201 **XbaI (4226)**
 4201 *TGAAACTCCGCTGGTCTTCAGGTAGAGGGTAACACTTTGACTGCCTGGCTCACGCTCGATCCACTGGCAGTGTTAGAACACGACTGTT*
 4301 *GCTTCGTAGCGGAGCATGACGGCGTGGAACTCCTCCTGGTAACAAGGACCCACGGGGCAAAGGCCACGCCACACGGGGCGTCATGTGTGCAACC*
 4401 *CCAGCACGGCGACTTACTCGAAACCCACTTAAAGTGACATTGAAACTGGTACCCACACACTGGTACAGGCTAAGGATGCCCTCAGTACCCGAG*
 4501 **HindIII (4565)**
 4501 *GTAACACGGACACTCGGGATCTGAGAAGGGACTGGGCTCTATAAGCGCTGGTTAAAAGCTTATGCCTGAATAGGTGACCGGAGGTGGC*
Asel (4652)
 4601 *ACCTTCCTTGCAATTACTGACCCATGAATACAACGTACTGTTGACAATTATCATCGCATAGTATATCGCATAGTATAATACGACTCACTATAG*
 4701 *GAGGGCCACCATGAAAGAACCTGAACTGACAGCAACTCTGTTGAGAAGTTCTATTGAAAATTGATTCTGTTCTGATCTCATGAGCTGCTGAA*
 4801 *MetLysLysProGl uLeuThrAl aThrSerVal Gl uLysPheLeuIleGl uLysPheAspSerVal SerAspLeuMetGl nLeuSerGl u*
 4801 *GGTGAAGAAAGCAGAGCCTTTCTTTGATGTTGGAGGAAGAGGTTATGTTCTGAGGGTCAATTCTGTCTGATGTTTTACAAAGACAGATATGTT*
 4801 *31 Gl yGl uGl uSerArgAl aPheSerPheAspVal Gl yGl yArgI yTyrVal LeuArgVal AsnSer CysAl aAspGl yPheTyrLysAspArgTyrValT*
 4901 *ACAGACACTTGCCTGCTCTGCAATTCCAGAAGTCTGGACATTGGAGAATTCTGATCTCACCCTACTGCTCAGCAGAACGACAAGG*
 4901 *64 yrArgHisPheAl aSerAl aAl aLeuProIleProIleGl uPheSerGl uSerLeuThrTyrCysIleSerArgArgAl aGl nGl*
 5001 *AGTCACTCTCCAGGATCTCCCTGAAACTGAGCTGCCAGCTGTTGCAACACTGTTGCTGAAGCAATTGGATCTGAGCAGCTGATCTGAGCCAACC*
 5001 *97 yrValThrLeuGl nAspLeuProGl uThrGl uLeuProAl aValLeuGl nProValAl aGl uAl aMetAspAl aIleAl aAl aAspLeuSerGl nThr*
 5101 *TCTGGATTGGTCCTTGGTCCCCAAGGCATTGGTAGCATACCAACTGGAGGGATTCATTGGCCATTGCTGATCCTCATGTCTATCACTGGCAGA*
 5101 *131 SerGl yPheGl yProPheGl yProGl nGl yIleGl yGl nTyrThrThrTrpArgAspPhel eCysAl aIleAl aAspProHi sVal TyrHi sTrpGl nT*
 5201 *CTGTGATGGATGACAGTTCTGCTCTGGTAGACTCATGCTGTGGCAGAAGATTGTCCTGAGTCAGACACCTGGTCCATGC*
 5201 *164 hrValMetAspAspThrValSerAlaSerValAlaGl nAl aLeuAspGl uLeuMetLeuTrpAl aGl uAspCysProGl uValArgHisLeuValAlHi sAl*
 5301 *TGATTTGGAAAGCAACATGTTCTGACAGACAATGGCAGAACATCTGACTCATTGCTGAAGCATGTTGGAGATTCTCAATATGAGGTGGC*
 5301 *197 aAspPheGl ySerAsnAsnValLeuThrAsnAl yArgI leThrAl aVal IleAspTrpSerGl uAl aMetPheGl yAspSerGl nTyrGl uValAl a*
 5401 *AACATTTTTGGAGACCTGGCTGGCTCATGGAACAACAAAGATAATTGAAAGAACACCCAGAACATGGCTGGTCCCCCAGACTGAGAG*
 5401 *231 AsnIlePhePheTrpArgProTrpLeuAl aCysMetGl uGl nGl nThrArgTyrPheGl uArgArgHisProGl uLeuAl aGl ySerProArgLeuArgA*
 5501 *CCTACATGCTCAGAATTGGCTGGACCAACTGTATCAATCTGGTTGATGGAACATTGATGATGCTGCTGGCACAAGGAAGATGTGATGCCATTGT*
 5501 *264 IaTyrMetLeuArgIleGl yLeuAspGl nLeuTyrGl nSerLeuValAspGl yAsnPheAspAspAl aAl aTrpAl aGl yArgCysAspAl aIleVa*
 5601 *GAGGTCTGGTCTGGAAACTGTTGGAGAACTCAAATGCAAGAAGGCTGCTGTTGACTGATGGATGTTGAAGTCTGGCTACTGGAAAC*
 5601 *297 IArgSerGl yAl aGl yThrValGl yArgThrGl nIleAl aArgArgSerAl aAl aValTrpThrAspGl yCysValGl uAl aLeuAl aAspSerGl yAsn*
 5701 *AGGAGACCTCCACAAGACCCAGGCCAGGAATGAAATTAGCTAGATTATCCCTAACACTGCCACCCACTCTAACATGTTGAGAAGAACGGTCT*
 5701 *331 ArgArgProSerThrArgProArgAlaLysGl u****
 5801 *CAGAACTGTTGTTCAATTGGCATTAAAGTTAGTAGAAAAGACTGGTAATGATAACAATGCTGTAAACCTTCAGAAGGAAAGGAAATGTT*
 5901 *TGTGGACCACTTGGTTCTTTGCGTGTGGAGTTAAAGTTAGTATTAGTTAAAATCAGTACTTTAATGGAAACAATTGACCAAAATTG*
 6001 *CACAGAATTGAGACCCATTAAAAAGTTAAATGAGAAACCTGTGTGTTCTTGGTCAACACCGAGACATTAGGTGAAAGACATCTAATTCTGGTT*
 6101 **HpaI (6140)**
 6101 *TACGAATCTGGAAACTCTTGTAAATGTAATTCTGAGTTAACACTCTGGGTGGAGAATAGGGTTTTCCCCACATAATTGAAAGGGAGGAAT*
 6201 *ATCATTAAAGCTATGGGAGGGTGTTGATTACAACACTGGAGAGAAATGCAGCATGTTGCTGATTGCTGTCACTAAACAGGCCAAAACGTC*
 6301 *CTTGGGTTGCATAGAAAGCTG*